Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19
Michael J Peluso,J Daniel Kelly,Scott Lu,Sarah A Goldberg,Michelle C Davidson,Sujata Mathur,Matthew S Durstenfeld,Matthew A Spinelli,Rebecca Hoh,Viva Tai,Emily A Fehrman,Leonel Torres,Yanel Hernandez,Meghann C Williams,Mireya I Arreguin,Jennifer A Bautista,Lynn H Ngo,Monika Deswal,Sadie E Munter,Enrique O Martinez,Khamal A Anglin,Mariela D Romero,Jacqueline Tavs,Paulina R Rugart,Jessica Y Chen,Hannah M Sans,Victoria W Murray,Payton K Ellis,Kevin C Donohue,Jonathan A Massachi,Jacob O Weiss,Irum Mehdi,Jesus Pineda-Ramirez,Alex F Tang,Megan Wenger,Melissa Assenzio,Yan Yuan,Melissa Krone,Rachel L Rutishauser,Isabel Rodriguez-Barraquer,Bryan Greenhouse,John A Sauceda,Monica Gandhi,Priscilla Y Hsue,Timothy J Henrich,Steven G Deeks,Jeffrey N Martin
DOI: https://doi.org/10.1101/2021.03.11.21252311
2021-03-12
MedRxiv
Abstract:Background: As the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC). Methods: From April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit. Results: We have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits. Conclusion: Among a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.